Skip to content
  • Categories
  • Recent
  • Tags
  • Popular
  • World
  • Users
  • Groups
Skins
  • Light
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Collapse

iSURG

  1. Home
  2. Medicine
  3. Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults ≥50 YearsA Randomized Clinical Trial

Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults ≥50 YearsA Randomized Clinical Trial

Scheduled Pinned Locked Moved Medicine
medicine
4 Posts 3 Posters 5 Views
  • Oldest to Newest
  • Newest to Oldest
  • Most Votes
Reply
  • Reply as topic
Log in to reply
This topic has been deleted. Only users with topic management privileges can see it.
  • otters_raft@lemmy.caO This user is from outside of this forum
    otters_raft@lemmy.caO This user is from outside of this forum
    otters_raft@lemmy.ca
    wrote last edited by otters_raft@lemmy.ca
    #1

    Question Is a multicomponent vaccine against seasonal influenza and SARS-CoV-2 (mRNA-1083) immunogenic and well-tolerated in adults 50 years and older?

    Findings In this phase 3 study, mRNA-1083 elicited noninferior immune responses against standard care immunization: licensed standard-dose or high-dose seasonal influenza vaccine (A/H1N1, A/H3N2, B/Victoria, B/Yamagata) coadministered with licensed SARS-CoV-2 (Omicron XBB.1.5) vaccine. The multicomponent vaccine mRNA-1083 had an acceptable tolerability and safety profile.

    Meaning mRNA-1083 was demonstrated to be at least as immunogenic as recommended standard care vaccines against both seasonal influenza and COVID-19 and well-tolerated in adults 50 years and older.

    Just a moment...

    favicon

    (jamanetwork.com)

    J 1 Reply Last reply
    1
    5
    • System shared this topic
    • otters_raft@lemmy.caO otters_raft@lemmy.ca

      Question Is a multicomponent vaccine against seasonal influenza and SARS-CoV-2 (mRNA-1083) immunogenic and well-tolerated in adults 50 years and older?

      Findings In this phase 3 study, mRNA-1083 elicited noninferior immune responses against standard care immunization: licensed standard-dose or high-dose seasonal influenza vaccine (A/H1N1, A/H3N2, B/Victoria, B/Yamagata) coadministered with licensed SARS-CoV-2 (Omicron XBB.1.5) vaccine. The multicomponent vaccine mRNA-1083 had an acceptable tolerability and safety profile.

      Meaning mRNA-1083 was demonstrated to be at least as immunogenic as recommended standard care vaccines against both seasonal influenza and COVID-19 and well-tolerated in adults 50 years and older.

      Just a moment...

      favicon

      (jamanetwork.com)

      J This user is from outside of this forum
      J This user is from outside of this forum
      just_another_person@lemmy.world
      wrote last edited by
      #2

      "Conclusions and Relevance In this study, mRNA-1083 met noninferiority criteria and induced higher immune responses than recommended standard care influenza (standard and high dose) and COVID-19 vaccines against all 4 influenza strains (among those ages 50-64 y), the 3 clinically relevant influenza strains (among those aged ≥65 y), and SARS-CoV-2 (all ages), with an acceptable tolerability and safety profile."

      Yes, it's totally doing what it's made to do.

      It seems like you're here to dispute that by doing this dumbshittery of "just asking questions", as if the outcome is not exactly what it says it is.

      recursive_recursion@lemmy.caR otters_raft@lemmy.caO 2 Replies Last reply
      1
      • J just_another_person@lemmy.world

        "Conclusions and Relevance In this study, mRNA-1083 met noninferiority criteria and induced higher immune responses than recommended standard care influenza (standard and high dose) and COVID-19 vaccines against all 4 influenza strains (among those ages 50-64 y), the 3 clinically relevant influenza strains (among those aged ≥65 y), and SARS-CoV-2 (all ages), with an acceptable tolerability and safety profile."

        Yes, it's totally doing what it's made to do.

        It seems like you're here to dispute that by doing this dumbshittery of "just asking questions", as if the outcome is not exactly what it says it is.

        recursive_recursion@lemmy.caR This user is from outside of this forum
        recursive_recursion@lemmy.caR This user is from outside of this forum
        recursive_recursion@lemmy.ca
        wrote last edited by recursive_recursion@lemmy.ca
        #3

        Reading the post, linked article, and your comment I'm wondering: aren't you guys on the same side (stating that vaccines work)?

        I could be wrong but I don't see @otters_raft@lemmy.ca disputing the efficacy of vaccines and is in fact doing the opposite in providing evidence that vaccines do work.

        1 Reply Last reply
        4
        • J just_another_person@lemmy.world

          "Conclusions and Relevance In this study, mRNA-1083 met noninferiority criteria and induced higher immune responses than recommended standard care influenza (standard and high dose) and COVID-19 vaccines against all 4 influenza strains (among those ages 50-64 y), the 3 clinically relevant influenza strains (among those aged ≥65 y), and SARS-CoV-2 (all ages), with an acceptable tolerability and safety profile."

          Yes, it's totally doing what it's made to do.

          It seems like you're here to dispute that by doing this dumbshittery of "just asking questions", as if the outcome is not exactly what it says it is.

          otters_raft@lemmy.caO This user is from outside of this forum
          otters_raft@lemmy.caO This user is from outside of this forum
          otters_raft@lemmy.ca
          wrote last edited by otters_raft@lemmy.ca
          #4

          This community is intended for healthcare professionals

          As per the article

          Importance Uptake of recommended seasonal influenza and COVID-19 vaccines remains suboptimal.

          Objective To assess the immunogenicity and safety of an investigational mRNA-1083 vaccine against seasonal influenza and SARS-CoV-2 in adults 50 years and older.

          Being able to cite data about safety and effectiveness is helpful when making recommendations to patients, and necessary when healthcare professionals are discussing policy.

          I included the results in the post body to make sure it wasn't clickbait or misleading, but I'm always looking to improving it in the future if you have feedback

          1 Reply Last reply
          1
          1
          • System shared this topic
          Reply
          • Reply as topic
          Log in to reply
          • Oldest to Newest
          • Newest to Oldest
          • Most Votes


          • Login

          • Don't have an account? Register

          • Login or register to search.
          • First post
            Last post
          0
          • Categories
          • Recent
          • Tags
          • Popular
          • World
          • Users
          • Groups